Tumor immunotherapy is only effective in a fraction of patients due to a low response rate
and severe side effects, and these challenges of immunotherapy in clinics can be addressed …

Understanding the in vivo transport of nanoparticles provides guidelines for designing
nanomedicines with higher efficacy and fewer side effects. Among many factors, the size of …

Nanoparticles enter tumours through endothelial cells, gaps or other mechanisms, but how
they exit is unclear. The current paradigm states that collapsed tumour lymphatic vessels …

Nanotechnology has been extensively studied and exploited for cancer treatment as
nanoparticles can play a significant role as a drug delivery system. Compared to …

Nanoparticle delivery to solid tumours over the past ten years has stagnated at a median of
0.7% of the injected dose. Varying nanoparticle designs and strategies have yielded only …

Therapeutic targeting of the immune system in cancer is now a clinical reality and marked
successes have been achieved, most notably through the use of checkpoint blockade …

The rapid development of nanotechnology offers a variety of potential therapeutic strategies
for cancer treatment. High atomic element nanomaterials are often utilized as …

Effective delivery of therapeutic and diagnostic nanoparticles is dependent on their ability to
accumulate in diseased tissues. However, most nanoparticles end up in liver macrophages …

Chemodynamic therapy (CDT), enabling selective therapeutic effects and low side effect,
attracts increasing attention in recent years. However, limited intracellular content of H2O2 …

Self-assembled peptides and proteins possess tremendous potential as targeted drug
delivery systems and key applications of these well-defined nanostructures reside in anti …